ABG Sundal Collier acted as advisor to Algiecel in connection with raising of DKK 50 / EUR 6.5m in new equity funding

On Friday 11 October 2024, Algiecel announced that it had raised approximately DKK 50m (EUR 6.5m) in equity funding. The company’s innovative microalgae-based technology links carbon capture with biology to reduce emissions and enable a sustainable food and feed system by producing high-value ingredients based on microalgae. After the successful inception of its pilot plant in 2022, Algiecel will use the new funds to scale up to a full-size demonstration plant at Novonesis in Kalundborg scheduled for Q3 2025.
Founded in 2021 and headquartered in Odense, Denmark, Algiecel is a pioneer within biosolutions for decarbonisation. By leveraging Algiecel’s proprietary carbon utilisation technology built into modular photobioreactors, Algiecel enables clients to transform industrial CO₂ into sustainable and nutrient rich ingredients containing protein and omega-3. Algiecel’s high-yield photobioreactor utilises microalgae and photosynthesis to convert captured CO₂ into microalgae biomass, that can be further split into a protein and oil fraction, which will ultimately serve as sustainable substitutes across a variety of application areas such as aquaculture feed, petfood, cosmetics and dietary supplements.